Multiplex Assay Kit for Tau Protein (MAPT) ,etc. by FLIA (Flow Luminescence Immunoassay) 
DDPAC; FTDP-17; MAPTL; MSTD; MTBT1; MTBT2; PPND; Neurofibrillary tangle protein; Microtubule Associated Protein Tau; Paired helical filament-tau; G Protein Beta1/Gamma2 Subunit-Interacting Factor 1
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 427.00 US$ 443.00 US$ 468.00 US$ 501.00 US$ 534.00 US$ 583.00 US$ 657.00 US$ 821.00
- Quantity
Overview
Properties
- Product No.LMB983Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryMetabolic pathwayNeuro scienceDevelopmental science
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Tau Protein (MAPT) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Tau Protein (MAPT) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 82-89 | 85 |
| EDTA plasma(n=5) | 85-95 | 90 |
| heparin plasma(n=5) | 86-95 | 90 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Tau Protein (MAPT) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Tau Protein (MAPT) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Tau Protein (MAPT) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 85-101% | 78-93% | 83-91% | 89-97% |
| EDTA plasma(n=5) | 79-101% | 95-103% | 88-99% | 78-92% |
| heparin plasma(n=5) | 78-102% | 83-96% | 84-93% | 89-101% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:MAPT) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
Test principle
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.
Giveaways
Increment services
Citations
- Effect of etanercept and lithium chloride on preventing secondary tissue damage in rats with experimental diffuse severe brain injuryPubmed:24452937
- Wpływ omdlenia u młodocianych na stężenie białka tau w surowicy krwib09f7df8-1e7d-4665-a2a5-bf54dae0cfe9
- Serum microtubule associated protein tau and myelin basic protein as the potential markers of brain ischaemia-reperfusion injury in patients undergoing carotid endarterectomyAA.2016.0008
- THE PRESENCE OF TAU PROTEIN IN BLOOD AS A POTENTIAL PROGNOSTIC FACTOR IN STROKE PATIENTSpubmed:28011949
- Serum microtubule associated protein tau and myelin basic protein as the potential markers of brain ischaemia-reperfusion injury in patients undergoing carotid endarterectomyAA.2016.0008
- Differential hyperphosphorylation of tau-S199,-T231 and-S396 in organotypic brain slices of Alzheimer mice. A model to study early tau hyperphosphorylation using …Pubmed:29725295
- The potential role of serum tau protein (MAPT), neuronal cell adhesion molecule (NrCAM) and neprilysin (NEP) in neurodegenerative disorders development in …